Recent discoveries into gut bacteria and nanomedicines could pave the way for better treatments of gut pain, new research suggests. 

According to studies published in Cell Host & Microbe and Proceedings of the National Academy of Sciences (PNAS), scientists have discovered a new enzyme in gut bacteria and are using nanoparticles to deliver drugs inside cells. It is hoped the discovery could treat gut pain from digestive disorders more effectively.  

Researchers focused on PAR2, a receptor involved in pain signalling that has been shown to play a role in gastrointestinal diseases marked by inflammation and pain. Found on the lining of the gut and on pain-sensing nerves in the gut, PAR2 is activated by certain enzymes called proteases and is a promising target for treating gut pain. 

“In focusing on this receptor, we’ve mapped out a pathway between a bacterial enzyme and pain and determined how to block PAR2 using nanoparticles—both of which may help us to treat pain related to digestive disorders in the future,” said Nigel Bunnett, Professor and Chair of the Department of Molecular Pathobiology at NYU College of Dentistry and a Faculty Member in the NYU Pain Research Center. 

Research into gut bacteria provides clues for pain

The research, led by Matthew Bogyo, Professor of Pathology, Microbiology, and Immunology at Stanford University School of Medicine, looked at the production of proteases by gut bacteria and whether these enzymes regulate PAR2 activity, causing pain.  

Abdominal pain is a hallmark of many digestive disorders, including inflammatory bowel disease and irritable bowel syndrome. There are currently no treatments specifically for gut pain and existing painkillers are often insufficient at managing symptoms. These drugs, including opioids, NSAIDs, and steroids, also come with side effects, some of which directly harm the digestive system.  

Using a large library of human strains of bacteria found in the gut, scientists tested each strain to see if they produced enzymes that would cleave and activate PAR2. Surprisingly, more than 50 bacteria secreted enzymes that cleaved PAR2. 

Researchers focused on a previously unknown enzyme produced by the bacterium Bacteroides fragilis (B. fragilis), which has particularly robust activity. B. fragilis is normally found in the human colon, with some evidence that it may contribute to inflammatory bowel disease. 

Results found that the enzyme produced by B. fragilis cleaves PAR2 to activate the receptor. In further studies in cells and mice, the researchers compared regular B. fragilis bacteria and a modified version of the bacteria in which the enzyme was removed. They found that the protease produced by B. fragilis bacteria excited neurons that detect and transmit pain, disrupted the intestinal barrier, and triggered inflammation and pain in the colon. 

“The results were black and white: if the protease was present, there was pain signalling, and if the protease was not present, there was no pain signalling. Our study identifies a new axis of communication between gut bacteria and the host that has implications for how symptoms may be triggered in inflammatory bowel disease,” said Bogyo. 

Nanoparticles create a ‘precision-targeted approach’ 

In a separate study in PNAS, researchers sought to exploit a known behaviour of PAR2. When the receptor is activated, it moves from the surface of cells lining the gut to compartments within the cells called endosomes. The receptor continues to function inside endosomes and generates inflammation and pain by signalling nerve cells and creating gaps in the protective barrier of cells lining the intestines.

“If this receptor internalises and signals from these compartments, we have to develop a drug delivery strategy that will target the receptor inside the compartments,” said Bunnett. 

To get a drug into endosomes, the researchers turned to nanoparticles. Nanoparticles are used to precisely direct drugs, minimising side effects and the amount of drug needed. This approach could be beneficial in digestive disorders, as nanoparticles could send drugs to the wall of the gut without spreading to other parts of the body. 

To test this approach, the researchers used an experimental drug called AZ3451 that blocks PAR2. They encapsulated AZ3451 in two different types of nanoparticles targeting the two major sites of receptor signalling that drive abdominal pain: epithelial cells lining the intestine and nerve cells. The nanoparticles were engineered to slowly release the drug over several days.  

“That sustained release is exactly what you want for a chronic disease,” said Bunnett. 

“Using nanoparticles for drug delivery demonstrates a precision-targeted approach. These nanoparticles are precisely directed not only to a particular cell, but a particular compartment within the cell and a particular receptor within the compartment.” 

Bruno Quinney, Content Team, DDW